At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02268 WUXI XDC
Market Closed 12-05 16:09:08
67.500
-0.500
-0.74%
High69.250Low67.400Vol3.03M
Open67.600D1 Closing68.000Amplitude2.72%
Mkt Cap84.58BTradable Cap84.58BTotal Shares1.25B
T/O206.23MT/O Rate0.24%Tradable Shares1.25B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BOCOM INTL: China's 1st-8th Batch National Drug Procurement Renewal Rules Likely Moderate, Short-Term Catalysts Ample
Stock News  ·  12-05 10:48
BOCOM INTL: China's 1st-8th Batch National Drug Procurement Renewal Rules Likely Moderate, Short-Term Catalysts Ample
WuXi XDC Cayman Inc.'s (HKG:2268) Stock Has Fared Decently: Is the Market Following Strong Financials?
Simply Wall St.  ·  12-05 06:28
WuXi XDC Cayman Inc.'s (HKG:2268) Stock Has Fared Decently: Is the Market Following Strong Financials?
WuXi XDC (02268) Announces November 2025 Equity Movements
Bulletin Express  ·  12-04 17:10
WuXi XDC (02268) Announces November 2025 Equity Movements
HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%
Tiger Newspress  ·  12-04
HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%
10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
Stock News  ·  12-03
10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
HK Movers | Biotech Stocks Fall. Ascletis-B down 11%; Hua Medicine-B, Mabpharm-B down about 7%; Antengene-B down 5%; Ascentage-B down 4%.
Tiger Newspress  ·  12-03
HK Movers | Biotech Stocks Fall. Ascletis-B down 11%; Hua Medicine-B, Mabpharm-B down about 7%; Antengene-B down 5%; Ascentage-B down 4%.
Wuxi XDC Cayman Inc. Files HKEX Disclosure on 3,000 New Shares Issued at HKD 7.501 Each
Reuters  ·  12-01
Wuxi XDC Cayman Inc. Files HKEX Disclosure on 3,000 New Shares Issued at HKD 7.501 Each
WUXI XDC (02268) Issues 1.1133 Million Shares Due to Option Exercise
Stock News  ·  12-01
WUXI XDC (02268) Issues 1.1133 Million Shares Due to Option Exercise
WuXi XDC (02268) Announces Next Day Disclosure Return, Issued Shares Reach 1,255,074,593
Bulletin Express  ·  12-01
WuXi XDC (02268) Announces Next Day Disclosure Return, Issued Shares Reach 1,255,074,593
HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%
Tiger Newspress  ·  11-26
HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%
WuXi XDC (2268) Announces Extraordinary General Meeting and Revised Service Agreements
Bulletin Express  ·  11-26
WuXi XDC (2268) Announces Extraordinary General Meeting and Revised Service Agreements
WuXi XDC Cayman Inc. (Stock Code: 2268) Issues Supplemental Announcement on Continuing Connected Transactions
Bulletin Express  ·  11-25
WuXi XDC Cayman Inc. (Stock Code: 2268) Issues Supplemental Announcement on Continuing Connected Transactions
HK Movers｜Biotech Shares Gained. 3SBio And Hengrui Pharma Up 5%; Tigermed Up 3%; SKB Bio, JW Therap, Remegen And Wuxi XDC Up 2%
Tiger Newspress  ·  11-24
HK Movers｜Biotech Shares Gained. 3SBio And Hengrui Pharma Up 5%; Tigermed Up 3%; SKB Bio, JW Therap, Remegen And Wuxi XDC Up 2%
Gf Securities: Domestic R&D Investment Demand Recovery Highlights Left-Side Opportunities in Pharma Sector
Stock News  ·  11-20
Gf Securities: Domestic R&D Investment Demand Recovery Highlights Left-Side Opportunities in Pharma Sector
CCB International Raises WUXI XDC (02268) Target Price to HK$90, Keeps "Outperform" Rating
Stock News  ·  11-20
CCB International Raises WUXI XDC (02268) Target Price to HK$90, Keeps "Outperform" Rating
Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast
Stock News  ·  11-18
Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast
Hong Kong Stocks Movement | WUXI XDC (02268) Rises Over 5% Before Noon as Overseas Innovative Drug Deals Expand and Order Momentum Remains Strong
Stock News  ·  11-13
Hong Kong Stocks Movement | WUXI XDC (02268) Rises Over 5% Before Noon as Overseas Innovative Drug Deals Expand and Order Momentum Remains Strong
CMB International: CXO Sector Performance May Recover in H2, Favors SINO BIOPHARM and WUXI XDC
Deep News  ·  11-11
CMB International: CXO Sector Performance May Recover in H2, Favors SINO BIOPHARM and WUXI XDC
CMB International: Healthcare Sector Favors Stable Strategies, Opportunities in Undervalued Stocks
Stock News  ·  11-10
CMB International: Healthcare Sector Favors Stable Strategies, Opportunities in Undervalued Stocks
WuXi XDC Cayman Inc. (02268) Announces October 2025 Monthly Return, Issued Shares Reach Approximately 1.254 Billion
Bulletin Express  ·  11-05
WuXi XDC Cayman Inc. (02268) Announces October 2025 Monthly Return, Issued Shares Reach Approximately 1.254 Billion

Introduction

Company Name.
WUXI XDC
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
WuXi XDC Cayman Inc is an investment holding company principally engaged in the provision of comprehensive contract research, development and manufacturing organization (CRDMO) services for antibody drug conjugate (ADC) and other bioconjugates. The Company's services include the discovery, process development and Good Manufacturing Practice (GMP) manufacturing for bioconjugates, monoclonal antibody intermediates and payload-linkers associated with bioconjugates. The Company provides CRDMO services to customers through contracts under fee-for-service (FFS) basis and contracts under full-time equivalent (FTE) basis. The Company principally conducts its businesses in domestic and overseas markets, including North America, Europe and the rest of the world.
Issue price:
--